Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Growth Rate of the Diagnostic Biomarkers Market?
The market size for diagnostic biomarkers has witnessed fast-paced expansion in the past few years. Its growth is projected to rise from $65.25 billion in 2024 to $75.67 billion in 2025, showcasing a compound annual growth rate (CAGR) of 16.0%. The growth during the historical timeframe is largely due to the increasing occurrence of chronic diseases, advancements made in omics technologies, mounting demand for personalized treatment, amplified knowledge about early disease detection, and the rise of non-invasive diagnostic techniques.
What Growth Rate Is Forecasted for the Diagnostic Biomarkers Market by 2029?
The size of the diagnostic biomarkers market is predicted to experience substantial growth in the coming years, expanding to $136.57 billion by 2029 with a compound annual growth rate (CAGR) of 15.9%. The growth during this forecasted period may be influenced by factors like the rising implementation of liquid biopsy techniques, the increase in investments made in biomarker research, an escalated emphasis on precision medicine, and their growing usage in the treatment of neurodegenerative diseases. In terms of trends during this period, we may see noteworthy progress in artificial intelligence and machine learning, the incorporation of multi-omics approaches, advancements in the creation of point-of-care diagnostic tools, a transition towards digital biomarkers, an uptake in the usage of wearable health monitoring devices, and a heightened focus on the validation and standardization of biomarkers.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21171&type=smp
Which Key Companies Are Shaping the Future of the Diagnostic Biomarkers Market?
Major companies operating in the diagnostic biomarkers market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, PerkinElmer Inc., Siemens Healthineers AG, Merck KGaA, Agilent Technologies Inc., Charles River Laboratories International Inc., Bio-Rad Laboratories Inc., Bruker Corporation, Qiagen N.V., Myriad Genetics Inc., Meso Scale Diagnostics LLC, EKF Diagnostics Holdings Plc, Sino Biological Inc., Enzo Biochem Inc., Biomarker Technologies Inc., Cisbio Bioassays, Signosis Inc., Epigenomics AG, LifeSign LLC, Banyan Biomarkers Inc., Biosims Technologies SAS
Which Factors Are Driving Demand in the Diagnostic Biomarkers Industry?
The upward trend in cancer incidences fuels the expansion of the diagnostic biomarkers market in the future. The rise in cancer cases is attributed to various elements such as older demographics, changes in lifestyle and environment, and enhanced diagnostic skills. Diagnostic biomarkers have an integral part in cancer by facilitating early discovery, accurate diagnosis, and individualized treatment plans, thus enhancing the prognosis for patients. As an illustration, the American Cancer Society, a US-based nonprofit cancer advocacy group, reported in January 2024 that cancer cases escalated from 1,958,310 in 2023 to 2,001,140, implying a 2.19% increase. This surge in cancer prevalence is propelling the diagnostic biomarkers market’s growth.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21171&type=smp
How Is the Diagnostic Biomarkers Market Segmented by Several Divisions?
The diagnostic biomarkers market covered in this report is segmented –
1) By Product: Safety Biomarkers, Efficacy Biomarkers, Validation Biomarkers
2) By Application: Oncology, Metabolic Disease, Neurological Disease
3) By End User: Hospitals, Cancer Research Institutes, Diagnostic Labs
Subsegments:
1) By Safety Biomarkers: Toxicity Biomarkers, Organ-Specific Safety Biomarkers, Drug-Induced Injury Biomarkers
2) By Efficacy Biomarkers: Predictive Biomarkers, Prognostic Biomarkers, Pharmacodynamic Biomarkers
3) By Validation Biomarkers: Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers
What are the Emerging Market Trends Driving the Growth of the Diagnostic Biomarkers Industry?
Leading firms in the diagnostic biomarkers market, such as Quanterix Corporation, are concentrating on developing non-invasive testing techniques like blood-based biomarker tests in an effort to improve accessibility and patient comfort through personalized treatment strategies. Blood-based biomarker tests serve as diagnostic tools, testing specific biological markers in the body fluids to detect or keep track of diseases like Alzheimer’s in a less invasive way. For instance, in July 2023, LucentAD, a blood-based biomarker test designed to support healthcare professionals in diagnosing Alzheimer’s disease in patients experiencing early cognitive symptoms was introduced by Quanterix Corporation, a US life sciences company. This test gauges plasma concentrations of p-Tau 181, a biomarker attributed to amyloid pathology in the brain, a principal mark of Alzheimer’s disease. LucentAD aspires to simplify the evaluation process for potential Alzheimer’s patients by providing a diagnostic tool that is more accessible and less intrusive than traditional methods such as cerebrospinal fluid analysis or amyloid positron emission tomography.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/diagnostic-biomarkers-global-market-report
Which Regions Are Driving Growth in the Diagnostic Biomarkers Market?
North America was the largest region in the diagnostic biomarkers market in 2024. The regions covered in the diagnostic biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21171
This Report Delivers Insight On:
1. How big is the diagnostic biomarkers market, and how is it changing globally?
2. Who are the major companies in the diagnostic biomarkers market, and how are they performing?
3. What are the key opportunities and risks in the diagnostic biomarkers market right now?
4. Which products or customer segments are growing the most in the diagnostic biomarkers market?
5. What factors are helping or slowing down the growth of the diagnostic biomarkers market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model